Georgia Bio Names 2024 Golden Helix Award Winners

Georgia Rep. Mark Newton, Academic Innovators, & Industry Leaders to be Honored at Georgia Life Sciences Summit in October

Georgia Bio, the state’s life science trade association, will honor the 2024 Golden Helix awardees October 21 at the opening reception of the Georgia Life Sciences Summit.

 

The Golden Helix Awards celebrate the contributions and achievements of Georgia legislative, academic, corporate, and advocacy leaders working to advance the growth of the life sciences industry and foster strategic partnerships that can create a healthier world. Traditionally, awardees are honored each spring at the awards gala, but this year Georgia Bio leadership decided to celebrate at the organization’s largest annual gathering. The Georgia Life Sciences Summit is expected to draw 350+ of the state’s life sciences industry leaders and will kick off with a Georgia Company Showcase highlight the best of the state’s emerging companies. 

 

“The life sciences community strives to improve patients’ lives, reduce our environmental footprint, use less and cleaner energy, and support workforce development, all while growing Georgia’s bioeconomy” said Georgia Bio CEO Maria Thacker Goethe, “The Golden Helix Awards highlights those lasting contributions made by many in the life sciences sector in Georgia.” 

 

Companies being honored with the distinguished Deal of the Year award include: Veranex for the acquisition of leading preclinical services provider T3 Labs; Werfen for the acquisition of transfusion and transplant diagnostics leader Immucor; life sciences manufacturer Meissner’s nearly $250 million investment into a new manufacturing facility in Athens-Clarke County; Dalan Animal Health’s $4.5M series seed 3 funding to accelerate global expansion and product pipeline; Inhibikase Therapeutics’ $10M raise for the development of treatments for Parkinson’s Disease and chronic myelogenous leukemia; Micron Biomedical’s $23.6M from the Bill & Melinda Gates Foundation to accelerate commercial manufacturing of their needle-free vaccines; and the NIH grant awarded to Emory, Georgia Tech & Children’s Healthcare to advance diagnostics. The Legislator of the Year Award will honor Georgia Representative Mark Newton of 127th House District for his leadership in sponsoring the rebate pass through bill in 2023, and his overall work on behalf of patients in Georgia.

 

The Metro Atlanta Chamber will present this year's Phoenix Award for life sciences to Wellstar MCG Health. This award celebrates the best industry and academic collaboration. The 2023 union of Wellstar and Augusta University is a move that bolsters healthcare in the region and will advance innovation.

 

The awards were selected by a small, distinguished committee of leaders in the Georgia ecosystem who assessed nominations and transactions closed between January 1, 2023 -December 31, 2023.

 

AWARD WINNERS  

 

Legislator of the Year Award: Presented to state legislators for their support of the life sciences industry in Georgia. 

  • The Honorable Mark Newton M.D., Georgia House of Representatives

 

Phoenix Award:  The Phoenix award represents the iconic "rising from the ashes" of the Phoenix, a symbol of strength, tenacity and leadership and is presented to celebrate the best Industry and Academic collaborations, outstanding healthcare professionals and systems, or other partnerships that drive translation and lead to new treatments and cures. This award is sponsored by the Metro Atlanta Chamber.  

  • Wellstar MCG Health

 

Deals of the Year Awards: Presented to one or more companies or institutions for the most significant financial or commercial transactions closed from January 1, 2022-December 31, 2022, based on the importance of the transaction to Georgia’s life sciences industry.  

 

Acquisitions  

  • Veranex completes acquisition of T3 Labs
  • Werfen completes acquisition of Immucor, Inc.

 

Economic Development

  • Meissner

 

Private Financing 

  • Dalan Animal Health
  • Inhibikase Therapeutics
  • Micron Biomedical

 

Public Financing 

  • Emory, Georgia Tech & Children’s Healthcare land major NIH grant for diagnostics

 

Community Awards: Presented to a small number of individuals, companies or institutions whose contributions to Georgia’s life sciences community are worthy of special recognition.  

  • Emily Blum, Global Center for Medical Innovation
  • Ashley Cornelison, Portal Innovations
  • Betty Pace, Georgia Cancer Center, Augusta University
  • Connor Seabrook, Georgia Research Alliance
  • The United States Patent and Trademark Office (USPTO) New Atlanta Regional Office

 

Innovation Awards: Presented to the department, institution, company or individuals who are forging new ground by thinking outside traditional paradigms to create some unique technology. 

  • Tom Barrows, ProgenaCare Global - ProgenaMatrix®
  • Jack Huang, University of Georgia - DE-FLUORO

 

Emerging Leader of the Year Awards: Presented to young individuals who have made a significant impact on the life sciences industry through their studies or employment. 

  • Eddie Lai, Metro Atlanta Chamber

 

Teacher of the Year Award: Presented to a Georgia biotechnology high school teacher who exhibits excellence in STEM teaching and support for the biotechnology pathway.  

  • Emily Gunderson, Empower College and Career Center, Jackson County

 

For a list of past award recipients, click here.  

 

# # # 

 

About Georgia Bio 

Georgia Bio (GaBio) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For over 30 years, GaBio has served its members by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in biotechnology, pharmaceuticals, and medical technology. GaBio also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. GaBio works to shape public policy, improve access to breakthrough technologies, educate lawmakers, provide member programs, strengthens the workforce pipeline, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. For more information, visit www.gabio.org. 

 

MEDIA CONTACT: 

Melissa Carter 

404-920-2043 

mcarter@gabio.org


EIN: https://www.einpresswire.com/article/734167122/georgia-bio-names-2024-golden-helix-award-winners

Georgia Life Sciences Weighs In on PBM and 340B Policy

October 5, 2026
Georgia Life Sciences has submitted written comments to the Georgia House Study Committee on Pharmacy Benefits Managers and Consumers’ Access to Prescription Medications, encouraging greater transparency, accountability, and a focus on measurable patient benefit across the prescription drug system. The comments address both pharmacy benefit manager practices and the federal 340B Drug Pricing Program, emphasizing the importance of understanding where prescription drug savings accrue and whether those savings ultimately benefit patients. The Study Committee continues its work this fall as it develops recommendations for the Georgia General Assembly. Read Georgia Life Sciences’ full comments →

Georgia Life Sciences Joins National Coalition Calling for PAHPA Reauthorization

September 22, 2026
Georgia Life Sciences (GLS) has joined more than 80 organizations from across industry, academia, public health and the biosecurity community in calling on congressional leaders to fully reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of 2026. Led by the Johns Hopkins Center for Health Security, the coalition urged congressional leaders to advance a comprehensive reauthorization of PAHPA, the federal framework that supports the nation’s ability to prepare for and respond to public health emergencies and other health security threats. First enacted in 2006, PAHPA established and strengthened critical components of the nation’s health security infrastructure, including the Biomedical Advanced Research and Development Authority (BARDA). The law also supports public-private partnerships involved in the research, development, manufacturing and procurement of medical countermeasures, including vaccines, therapeutics and diagnostics. PAHPA’s authorization expired in 2023 and key provisions have since continued through short-term extensions. The coalition is calling for a comprehensive reauthorization that provides greater stability and ensures the nation’s preparedness infrastructure can continue adapting to emerging biological, infectious disease and other health security threats. For the life sciences industry, these programs are particularly important. Partnerships between government and industry can help move promising technologies from research through development and manufacturing while maintaining capabilities needed to respond quickly during an emergency. The Biotechnology Innovation Organization (BIO), also a signatory to the letter, has identified several priorities for reauthorization, including continued authorization of BARDA, the Strategic National Stockpile, Project BioShield and the Pandemic Influenza Program, as well as incentives supporting the development of medical countermeasures. Georgia Life Sciences is proud to join organizations across the country in supporting a strong and sustainable national framework for health security, preparedness and biomedical innovation. Read the coalition letter and view the full list of signatories.

Georgia Life Sciences Urges Protection of Patient Access as Georgia Implements Medicaid Changes

September 14, 2026
Georgia Life Sciences has submitted comments to the Georgia Department of Community Health (DCH) regarding the Georgia Pathways to Coverage program and implementation of new federal Medicaid requirements. As Georgia prepares for these changes, Georgia Life Sciences is urging state leaders to prioritize continuity of care and minimize unnecessary administrative barriers that could delay or disrupt access to medically necessary treatment . This is particularly important for Georgians living with serious, chronic, rare, and medically complex conditions who may rely on ongoing medications, diagnostics, therapies, medical technologies, specialty care, and coordinated treatment plans. Even temporary disruptions in coverage can interrupt care and create additional challenges for patients and families. In its comments, Georgia Life Sciences encouraged DCH to protect continuity of coverage during eligibility and redetermination processes, provide patients and caregivers with clear and timely information, minimize unnecessary administrative burdens, and establish appropriate safeguards when a coverage disruption could interrupt an established course of treatment. “As Georgia implements these new federal requirements, we want to ensure that patients remain at the center of the process,” said Maria Thacker Goethe, MPH, President & CEO of Georgia Life Sciences. “Administrative changes should not become barriers between patients and the care they need. Protecting continuity of care is particularly important for Georgians managing serious and complex health conditions.” Read Georgia Life Sciences’ full comments to DCH here.
MORE POSTS